Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Visual snow syndrome - a clinical and phenotypical description of over 1000 cases
Neuro-ophthalmology/Neuro-otology
P4 - Poster Session 4 (5:30 PM-6:30 PM)
5-004
To validate the current criteria of visual snow (VS) and to describe its common phenotype using a substantial clinical database.

Patients with VS suffer a pan-field, dynamic visual disturbance described as continuous TV-static-like tiny flickering dots. The current diagnostic criteria require at least two additional visual symptoms from: palinopsia (afterimages and trailing), entoptic phenomena (floaters, blue field entoptic phenomenon, photopsia, self-light of the eye), photophobia and nyctalopia.

We performed a web-based survey on patients with self-assessed visual snow (n=1104,either with the complete visual snow syndrome (n=1061) or with visual snow without the syndrome (n=43). We also describe a population of patients (n=70) with possible hallucinogen persisting perception disorder who presented clinically with visual snow syndrome.

The visual snow population had an average age of 29 years and no gender prevalence. The disorder usually started in early life and around 40% of patients had symptoms for as long as they could remember. The most commonly experienced static was black and white. Floaters, afterimages and photophobia were the most reported additional visual symptoms. A latent class analysis showed that visual snow does not present with specific clinical endophenotypes. Severity can be classified by the amount of visual symptoms experienced. Migraine and tinnitus had a very high prevalence and were independently associated with a more severe presentation of the syndrome.

Our data confirm earlier work on this under-recognized disorder. Clinical characteristics of visual snow did not differ from the previous cohort in the literature, supporting validity of the current criteria. Visual snow likely represents a clinical continuum, with different degrees of severity. On the severe end of the spectrum it is more likely to present with its common comorbidities, migraine and tinnitus. Visual snow does not depend on the effect of psychotropic substances on the brain.

Authors/Disclosures
Francesca Puledda (King's College London)
PRESENTER
Ms. Puledda has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Ms. Puledda has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA.
Christoph J. Schankin, MD (Department of Neurology, Inselspital, Bern University Hospital) The institution of Dr. Schankin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. The institution of Dr. Schankin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. The institution of Dr. Schankin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. The institution of Dr. Schankin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. The institution of Dr. Schankin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Schankin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. The institution of Dr. Schankin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Grünenthal. The institution of Dr. Schankin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lilly. The institution of Dr. Schankin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. The institution of Dr. Schankin has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. The institution of Dr. Schankin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lundbeck. Dr. Schankin has stock in Zynnon.
Peter Goadsby, MD, PhD, FRS (King Abdullah Univeristy of Science and Technology) Dr. Goadsby has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Goadsby has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CoolTech LLC. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PureTech Health LLC. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Kallyope. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Seaport Therapeutics. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dr Reddy's. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orion Pharma. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ipsen. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Massachusetts Medical Society. The institution of Dr. Goadsby has received research support from NIHR. Dr. Goadsby has received publishing royalties from a publication relating to health care. Dr. Goadsby has received publishing royalties from a publication relating to health care. Dr. Goadsby has a non-compensated relationship as a Trustee with Migraine Trust that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Dr. Goadsby has a non-compensated relationship as a Trustee with Organisation for Understanding Cluster Headache (UK) that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities.